Waxman Strategies is strengthening its firmwide capabilities in political advocacy, regulatory insight, and industry expertise with the appointment of Ruth McDonald and Kahaari Kenyatta to the health policy team.
Based on the input of experts and nonprofit leaders, our white paper describes challenges in five policy areas and provides a set of policy options for policymakers to consider which could improve the sustainability of the nonprofit model and help to reduce the burden of high prescription drug prices.
In a blog post for Health Affairs, Chairman Henry Waxman debunks the age-old industry claim that lower drug costs mean a loss of drug innovation, noting they made the same unsubstantiated claim back in the 1980s during debate on the Hatch-Waxman Act.
In a piece written for Health Affairs this week, our Chairman Henry Waxman discusses the broken pharmaceutical marketplace, how empowering Medicare to negotiate prices with the pharmaceutical industry will make prescription drugs more affordable for everyone, and why we need the Lower Drug Costs Now Act.
This week, many of us here at Waxman Strategies packed our bags and temporarily relocated to New York City, where we were thrilled to host a reception as an official part of Climate Week NYC. The event, an evening of cocktails, hors d’oeuvres, and conversation, was held at Candle 79, an upscale restaurant with a plant-based menu.
Selecting and designing an office space is no easy feat. There’s a whole lot to consider, starting with how we create an environment that reinforces who we are and reflects our culture and values. Well, our new space is done and we think we’ve nailed it.
Two new specialists will focus on advancing healthcare system policy and legislation for the firm’s growing client base.
This month, Mighty Earth unveiled its Rapid Response Monitoring System aimed at eliminating deforestation linked to the palm oil, soy, rubber, cocoa, paper, and cattle industries.